Novartis Ag ADR (NVS)

$131.26 -0.65 (-0.49%)
Market Cap 277.28B
Revenue (ttm) 51.72B
Net Income (ttm) 11.94B
EPS (ttm) N/A
PE Ratio 14.77
Forward PE 14.85
Profit Margin 23.09%
Debt to Equity Ratio 0.67
Volume 1,822,800
Avg Vol 1,556,274
Day's Range N/A - N/A
Shares Out 2.11B
Stochastic %K 74%
Beta 0.60
Analysts Sell
Price Target $127.00

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CD...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 324 11 11
Fax: 41 61 324 80 01
Address:
Lichtstrasse 35, Basel, Switzerland
AStrokeOfLuck
AStrokeOfLuck Nov. 13 at 2:16 PM
$NVS
0 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 2:10 PM
$NVS: A breakthrough in malaria treatment? GanLum, Novartis' new malaria candidate, hit a 97.4% PCR-corrected cure rate in Phase III trials, demonstrating non-inferiority to the standard Coartem with its dual-action against resistant strains. Shares are up 36% YTD as Novartis aims for regulatory approval. Discover the full potential of GanLum 👉 https://www.zacks.com/stock/news/2790471/novartis-phase-iii-malaria-study-meets-key-non-inferiority-endpoint?cid=sm-stocktwits-2-2790471-body-20827&ADID=SYND_STOCKTWITS_TWEET_2_2790471_BODY_20827
0 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 1:10 PM
$NVS hits a major milestone in malaria treatment GanLum met its Phase III non-inferiority endpoint, showing strong efficacy even against drug-resistant malaria — a key win for Novartis’ pipeline. See what this means for NVS’s growth story 👉 https://www.zacks.com/stock/news/2790471/novartis-phase-iii-malaria-study-meets-key-non-inferiority-endpoint?cid=sm-stocktwits-2-2790471-teaser-20805&ADID=SYND_STOCKTWITS_TWEET_2_2790471_TEASER_20805
0 · Reply
Quantumup
Quantumup Nov. 13 at 12:51 PM
Jefferies🏁 $ORKA Buy/$45 $ABBV $JNJ $PTGX $NVS LLY UCBJY Jefferies in its initiation said: We like two YTE modified, long-acting mAbs with de-risked IL23/ IL17 targets for favorable less frequent dosing, and pot'ly greater efficacy. FIH PK of ORKA-001 (IL23) at EADV25 showed ~100-day half life, reaching bull case and supporting annual dosing. ORKA-002 (IL17) FIH PK is ~YE25 targeting ~50-/75-day half life. We see meaningful upside pot'l from Ph2a '001 POC study in PsO with readout in 2H26, followed by '002 ~6mo later. We initiate at Buy, with PT $45.
0 · Reply
isaacwilliams33
isaacwilliams33 Nov. 13 at 4:36 AM
$NVS recommend by Zack
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 11:28 PM
$RADX TRP Target Selection & Drug Design Summit 2026 (February 24–26, Boston, MA) - Over three days, experts from Novartis, Bayer, Abdera, Radiopharm Theranostics, AstraZeneca, OncoOne, PentixaPharm, Bicycle Therapeutics, Université Laval $BAYRY $NVS $BCYC $AZN
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 10 at 4:29 PM
$NVS
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 10 at 2:53 PM
Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presence $NVS $DFAX $QLTI https://stocktwits.com/news/equity/markets/novartis-opens-new-manufacturing-facility-in-california/cLPcmxZRE2X
0 · Reply
SGL_FGHI
SGL_FGHI Nov. 9 at 9:27 PM
$VKTX --- Before $LLY entered the weight loss market with tirzepatide (Zepbound), $NVS was leading in that market with semaglutide (Wegovy). LLY now leads with approximately 60% and NVS has about 20-30%. NVS’ offer for MSTR was to enhance NVS’ capabilities and expand its portfolio. Now, PFE not NVS is acquiring MSTR. Without the MSTR acquisition, what’s NVS to do? NVS is financially able and has a history of making substantial acquisitions to expand its portfolio when this aligns with its long-term strategic goals.
2 · Reply
wwmeinc
wwmeinc Nov. 7 at 2:07 PM
$RNA $NVS Just waiting patiently as a RNA shareholder...deal as it looks very fair...Spinco is going to be a winner,eventually though...as talent married w/science is key...just some thoughts...glta "Terms of the agreement Price: Novartis will acquire all outstanding shares of Avidity for $72.00 per share. Timeline: The deal is expected to close in the first half of 2026, pending regulatory and shareholder approval and the separation of Avidity's cardiology assets. Avidity spin-off: As part of the deal, Avidity's early-stage precision cardiology programs will be spun off into a new, publicly traded company known as "SpinCo". Avidity shareholders will receive one share of SpinCo for every ten shares of Avidity they own."
0 · Reply
Latest News on NVS
New, effective anti-malaria drug could help fight rising resistance, says Novartis

Nov 12, 2025, 5:07 PM EST - 3 days ago

New, effective anti-malaria drug could help fight rising resistance, says Novartis

Novartis opens new plant in California to make cancer drugs

Nov 10, 2025, 9:34 AM EST - 6 days ago

Novartis opens new plant in California to make cancer drugs

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

Nov 4, 2025, 1:15 AM EST - 12 days ago

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

Meharry and Novartis Partner on HEART Initiative for Healthier Communities

Nov 3, 2025, 8:00 AM EST - 13 days ago

Meharry and Novartis Partner on HEART Initiative for Healthier Communities

Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript

Oct 30, 2025, 4:46 PM EDT - 17 days ago

Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren's disease Phase III trials

Oct 29, 2025, 10:30 AM EDT - 18 days ago

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren's disease Phase III trials

3 Investable Laggards In An Overbought Market

Oct 28, 2025, 5:13 PM EDT - 19 days ago

3 Investable Laggards In An Overbought Market

AVDL BMY ETNB MRUS MTSR PAGP RNA

Novartis AG (NVS) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 1:41 PM EDT - 19 days ago

Novartis AG (NVS) Q3 2025 Earnings Call Transcript

Novartis completes acquisition of Tourmaline Bio

Oct 28, 2025, 9:52 AM EDT - 19 days ago

Novartis completes acquisition of Tourmaline Bio

TRML

Novartis CEO: We're never done with M&A

Oct 28, 2025, 8:16 AM EDT - 19 days ago

Novartis CEO: We're never done with M&A

Novartis shares fall as profit lags estimates; downside from Entresto patent loss to continue

Oct 28, 2025, 6:02 AM EDT - 19 days ago

Novartis shares fall as profit lags estimates; downside from Entresto patent loss to continue

Novartis posts Q3 income beat, reaffirms FY2025 guidance

Oct 28, 2025, 5:47 AM EDT - 19 days ago

Novartis posts Q3 income beat, reaffirms FY2025 guidance

Novartis looking to add more medicines to direct to patient platform, CEO says

Oct 28, 2025, 5:31 AM EDT - 19 days ago

Novartis looking to add more medicines to direct to patient platform, CEO says

Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done'

Oct 28, 2025, 4:17 AM EDT - 19 days ago

Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done'

Novartis Posts Higher Net Profit as Key Drugs Lift Sales

Oct 28, 2025, 3:06 AM EDT - 19 days ago

Novartis Posts Higher Net Profit as Key Drugs Lift Sales

Novartis announces expiration of Tourmaline Bio tender offer

Oct 28, 2025, 2:25 AM EDT - 19 days ago

Novartis announces expiration of Tourmaline Bio tender offer

TRML

Novartis Q3 operating income up 6% on new drug sales

Oct 28, 2025, 2:11 AM EDT - 19 days ago

Novartis Q3 operating income up 6% on new drug sales

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

Oct 28, 2025, 2:00 AM EDT - 19 days ago

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Oct 27, 2025, 2:52 PM EDT - 20 days ago

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

RNA

Novartis AG (NVS) M&A Call Transcript

Oct 27, 2025, 2:27 PM EDT - 20 days ago

Novartis AG (NVS) M&A Call Transcript

Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk

Oct 27, 2025, 8:16 AM EDT - 20 days ago

Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk

RNA

Wall Street Breakfast Podcast: Novartis Puts $12B On The Table

Oct 27, 2025, 6:54 AM EDT - 20 days ago

Wall Street Breakfast Podcast: Novartis Puts $12B On The Table

HSBC RNA

Novartis shares slip, Avidity soars after $12 billion biotech deal

Oct 27, 2025, 6:29 AM EDT - 20 days ago

Novartis shares slip, Avidity soars after $12 billion biotech deal

RNA

Novartis Agrees $12 Billion Biotech Deal for Avidity

Oct 27, 2025, 4:59 AM EDT - 20 days ago

Novartis Agrees $12 Billion Biotech Deal for Avidity

RNA

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

Oct 26, 2025, 5:33 PM EDT - 20 days ago

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

RNA

Novartis to acquire Avidity Biosciences for about $12B

Oct 26, 2025, 3:46 PM EDT - 21 days ago

Novartis to acquire Avidity Biosciences for about $12B

RNA

Novartis Deal Values Avidity Biosciences At $12 Billion

Oct 26, 2025, 3:29 PM EDT - 21 days ago

Novartis Deal Values Avidity Biosciences At $12 Billion

RNA

Novartis to acquire Avidity Biosciences for $12 billion

Oct 26, 2025, 1:07 PM EDT - 21 days ago

Novartis to acquire Avidity Biosciences for $12 billion

RNA

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

Oct 26, 2025, 1:07 PM EDT - 21 days ago

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

RNA

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Oct 26, 2025, 1:00 PM EDT - 21 days ago

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

RNA

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Oct 26, 2025, 12:26 PM EDT - 21 days ago

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

RNA

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

Oct 26, 2025, 11:09 AM EDT - 21 days ago

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

RNA

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

Oct 25, 2025, 11:00 AM EDT - 22 days ago

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Oct 22, 2025, 1:15 AM EDT - 25 days ago

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

Oct 22, 2025, 1:00 AM EDT - 25 days ago

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

TRML

Novartis' Pluvicto shown to reduce risk of progression or death by 28% in prostate cancer

Oct 19, 2025, 10:56 AM EDT - 4 weeks ago

Novartis' Pluvicto shown to reduce risk of progression or death by 28% in prostate cancer

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

Oct 19, 2025, 10:30 AM EDT - 4 weeks ago

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

Oct 17, 2025, 8:00 AM EDT - 4 weeks ago

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

Oct 17, 2025, 6:37 AM EDT - 4 weeks ago

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

Novartis: Assessing The Impact Of Entresto Generics

Oct 16, 2025, 1:23 PM EDT - 4 weeks ago

Novartis: Assessing The Impact Of Entresto Generics

Novartis' Fabhalta slows progression of rare kidney disease in trial

Oct 16, 2025, 1:40 AM EDT - 4 weeks ago

Novartis' Fabhalta slows progression of rare kidney disease in trial

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

Oct 16, 2025, 1:15 AM EDT - 4 weeks ago

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX

Oct 10, 2025, 7:30 AM EDT - 5 weeks ago

Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX

AKRO

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 5 weeks ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance

Oct 3, 2025, 8:56 AM EDT - 6 weeks ago

Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Sep 30, 2025, 5:23 PM EDT - 6 weeks ago

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

US FDA approves Novartis' drug for skin disease

Sep 30, 2025, 4:22 PM EDT - 6 weeks ago

US FDA approves Novartis' drug for skin disease

Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.

Sep 29, 2025, 8:53 AM EDT - 6 weeks ago

Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

Sep 29, 2025, 8:15 AM EDT - 6 weeks ago

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

Novartis announces commencement of tender offer to acquire Tourmaline Bio

Sep 29, 2025, 7:44 AM EDT - 6 weeks ago

Novartis announces commencement of tender offer to acquire Tourmaline Bio

TRML

AStrokeOfLuck
AStrokeOfLuck Nov. 13 at 2:16 PM
$NVS
0 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 2:10 PM
$NVS: A breakthrough in malaria treatment? GanLum, Novartis' new malaria candidate, hit a 97.4% PCR-corrected cure rate in Phase III trials, demonstrating non-inferiority to the standard Coartem with its dual-action against resistant strains. Shares are up 36% YTD as Novartis aims for regulatory approval. Discover the full potential of GanLum 👉 https://www.zacks.com/stock/news/2790471/novartis-phase-iii-malaria-study-meets-key-non-inferiority-endpoint?cid=sm-stocktwits-2-2790471-body-20827&ADID=SYND_STOCKTWITS_TWEET_2_2790471_BODY_20827
0 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 1:10 PM
$NVS hits a major milestone in malaria treatment GanLum met its Phase III non-inferiority endpoint, showing strong efficacy even against drug-resistant malaria — a key win for Novartis’ pipeline. See what this means for NVS’s growth story 👉 https://www.zacks.com/stock/news/2790471/novartis-phase-iii-malaria-study-meets-key-non-inferiority-endpoint?cid=sm-stocktwits-2-2790471-teaser-20805&ADID=SYND_STOCKTWITS_TWEET_2_2790471_TEASER_20805
0 · Reply
Quantumup
Quantumup Nov. 13 at 12:51 PM
Jefferies🏁 $ORKA Buy/$45 $ABBV $JNJ $PTGX $NVS LLY UCBJY Jefferies in its initiation said: We like two YTE modified, long-acting mAbs with de-risked IL23/ IL17 targets for favorable less frequent dosing, and pot'ly greater efficacy. FIH PK of ORKA-001 (IL23) at EADV25 showed ~100-day half life, reaching bull case and supporting annual dosing. ORKA-002 (IL17) FIH PK is ~YE25 targeting ~50-/75-day half life. We see meaningful upside pot'l from Ph2a '001 POC study in PsO with readout in 2H26, followed by '002 ~6mo later. We initiate at Buy, with PT $45.
0 · Reply
isaacwilliams33
isaacwilliams33 Nov. 13 at 4:36 AM
$NVS recommend by Zack
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 11:28 PM
$RADX TRP Target Selection & Drug Design Summit 2026 (February 24–26, Boston, MA) - Over three days, experts from Novartis, Bayer, Abdera, Radiopharm Theranostics, AstraZeneca, OncoOne, PentixaPharm, Bicycle Therapeutics, Université Laval $BAYRY $NVS $BCYC $AZN
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 10 at 4:29 PM
$NVS
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 10 at 2:53 PM
Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presence $NVS $DFAX $QLTI https://stocktwits.com/news/equity/markets/novartis-opens-new-manufacturing-facility-in-california/cLPcmxZRE2X
0 · Reply
SGL_FGHI
SGL_FGHI Nov. 9 at 9:27 PM
$VKTX --- Before $LLY entered the weight loss market with tirzepatide (Zepbound), $NVS was leading in that market with semaglutide (Wegovy). LLY now leads with approximately 60% and NVS has about 20-30%. NVS’ offer for MSTR was to enhance NVS’ capabilities and expand its portfolio. Now, PFE not NVS is acquiring MSTR. Without the MSTR acquisition, what’s NVS to do? NVS is financially able and has a history of making substantial acquisitions to expand its portfolio when this aligns with its long-term strategic goals.
2 · Reply
wwmeinc
wwmeinc Nov. 7 at 2:07 PM
$RNA $NVS Just waiting patiently as a RNA shareholder...deal as it looks very fair...Spinco is going to be a winner,eventually though...as talent married w/science is key...just some thoughts...glta "Terms of the agreement Price: Novartis will acquire all outstanding shares of Avidity for $72.00 per share. Timeline: The deal is expected to close in the first half of 2026, pending regulatory and shareholder approval and the separation of Avidity's cardiology assets. Avidity spin-off: As part of the deal, Avidity's early-stage precision cardiology programs will be spun off into a new, publicly traded company known as "SpinCo". Avidity shareholders will receive one share of SpinCo for every ten shares of Avidity they own."
0 · Reply
Williamtraderlife
Williamtraderlife Nov. 7 at 7:15 AM
$NVS bullish as always $CYN this one going to break out keep on watchlist read the charts!
0 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 5:45 PM
$TVTX News just posted on FSGS study. (Strange time of day to release news). Data is fantastic. Feel like FSGS approval is a slam dunk. $LLY and $NVS are likely watching very closely, if not already accumulating. Hope that kicks $AZN and $JNJ into higher gear on $TVTX
2 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 4:09 PM
$TVTX Then, in Feb, $NVS or $LLY announce acquisition, in the $60.00 to $75.00 range (with $AZN and $JNJ watching )
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 6 at 2:29 PM
Novartis’ Pluvicto Heavywork Proves Radiopharma Can Succeed - BioSpace $RADX $NVS $LNTH $IOVA https://www.biospace.com/business/novartis-pluvicto-heavywork-proves-radiopharma-can-succeed
0 · Reply
biolover
biolover Nov. 5 at 11:42 PM
$VKTX that is not teeth and nail . $NVS guy ( who is screwing a great company ) just paid $12B for mediocre three rare disease asset RNA company
1 · Reply
Zkoko_Bio
Zkoko_Bio Nov. 5 at 10:18 PM
$PFE come on over and buy $LXRX !! $MTSR $NVS
0 · Reply
TwongStocks
TwongStocks Nov. 5 at 10:11 PM
$PFE issued a statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent $MTSR from terminating the existing merger agreement in favor of a competing proposal from $NVS "We remain confident in the merits of our claims and our belief that Metsera has acted in breach of its contractual obligations and that Metsera’s directors have breached their obligations to act in the best interest of Metsera’s shareholders. Today’s decision does not address the merits of the underlying legal issues raised, and Pfizer intends to continue to pursue its claims vigorously through the ongoing litigation process as well as in its parallel antitrust litigation pending in Delaware federal court. We are confident that Novo Nordisk’s unprecedented and illegal scheme to circumvent antitrust scrutiny will not stand..." https://www.businesswire.com/news/home/20251105465243/en/Pfizer-Responds-to-Delaware-Chancery-Court-Ruling
0 · Reply
TwongStocks
TwongStocks Nov. 5 at 7:33 PM
$MTSR $NVS $PFE https://x.com/business/status/1986153699102621804 Staff members at the US Federal Trade Commission said it appears Novo Nordisk A/S’ proposed bid for Metsera Inc. “may violate the procedural provisions” of the law that requires a premerger review.
0 · Reply
Jay_Bingo
Jay_Bingo Nov. 5 at 6:30 PM
$IOVA $MRK $NVS big pharma buying Iovance gets a product and probably two more BLAs in one year, economies of scale to rapidly improve margins using their existing chain, and loads of losses that Iovance has accumulated o offset their tax on their regular business.
0 · Reply
Fingerlickengood
Fingerlickengood Nov. 5 at 6:26 PM
$CDXS $NVS Pay close attention. " Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors." https://ir.codexis.com/news-events/press-releases/detail/415/codexis-appoints-arthur-levin-phd-to-strategic-advisory-board
1 · Reply
Fingerlickengood
Fingerlickengood Nov. 5 at 6:18 PM
$CDXS $NVS https://www.chemistryworld.com/news/novartis-spends-on-deals-to-offset-patent-losses/4022446.article
0 · Reply
Quantumup
Quantumup Nov. 5 at 4:19 PM
Piper Sandler⬆️ $DAWN to $26 from $25, reiterated at Overweight—thinks valuation provides an attractive entry point ahead of cont'd comm execution, add'l long-term data/eventual '27 1L pLGG data. $NVS $PFE BofA reit'd DAWN Buy-$17, and said, 3Q earnings review: 'DAWN Patient Starts Look Positive.' BofA additionally said:
0 · Reply